Related Articles
‘Genetic profiling’ and ovarian cancer therapy (Review)
Research progress on common adverse events caused by targeted therapy for colorectal cancer (Review)
Immunosuppressive effects of vascular endothelial growth factor (Review)
Bevacizumab-containing regimens after cetuximab failure in Kras wild-type metastatic colorectal carcinoma
Association between polymorphisms in EGFR and tumor response during cetuximab and oxaliplatin‑based combination therapy in metastatic colorectal cancer: Analysis of data from two clinical trials